نتایج جستجو برای: telaprevir

تعداد نتایج: 686  

Journal: :Antiviral research 2014
Malcolm J Macartney Dianne Irish Simon H Bridge Ana Garcia-Diaz Clare L Booth Adele L McCormick Wendy Labbett Colette Smith Carmen Velazquez Sudeep Tanwar Paul Trembling Michael Jacobs Geoff Dusheiko William Rosenberg Tanzina Haque

The use of triple-therapy, pegylated-interferon, ribavirin and either of the first generation hepatitis C virus (HCV) protease inhibitors telaprevir or boceprevir, is the new standard of care for treating genotype 1 chronic HCV. Clinical trials have shown response rates of around 70-80%, but there is limited data from the use of this combination outside this setting. Through an expanded access ...

2014
Phil McEwan Samantha Webster Yong Yuan Anupama Kalsekar Kristine Broglio Isao Kamae Melanie Quintana Masahiro Kobayashi Sachie Inoue Hiromitsu Kumada

Objectives: Japan has one of the highest endemic rates of hepatitis C virus (HCV) infection. Treatments in Japan are currently limited to interferon-alfa–based regimens, which are associated with tolerability and efficacy issues. A novel regimen combining two oral HCV therapies, daclatasvir and asunaprevir (DCV þ ASV), has shown favorable results in Japanese patients with chronic genotype 1b HC...

Journal: :Arquivos de gastroenterologia 2015
Paulo R L Almeida Carla Bortolin Fonseca Vivian W Koch Amanda M Souza Alberi A Feltrin Cristiane Valle Tovo

BACKGROUND Chronic hepatitis C has great impact on world's health. Current therapy for genotype 1 hepatitis C virus includes protease inhibitors boceprevir and telaprevir, associated to standard therapy - peginterferon alfa + ribavirin. There are no published data in Brazil on the results of this new therapy, and it is interesting an evaluation of what was accomplished up to this moment. Object...

2015
Alexandra Alexopoulou Peter Karayiannis

The development of protease inhibitors (PIs) such as telaprevir and boceprevir constitutes a milestone in chronic hepatitis C antiviral treatment since it has achieved sustained virological response (SVR) rates of up to 75% in naïve and 29-88% in treatment-experienced patients with genotype 1 infection. Both require combination treatment with pegylated interferon (PEG-IFN) plus ribavirin (RBV) ...

2017
Emma Gray David J. Pasta Suzanne Norris Aisling O’Leary

BACKGROUND Observational studies are used to measure the effectiveness of an intervention in non-experimental, real world scenarios at the population level and are recognised as an important component of the evidence pyramid. Such data can be accrued through prospective cohort studies and a patient registry is a proven method for this type of study. The national hepatitis C (HCV) registry was e...

Journal: :Journal of virology 2015
David R McGivern Takahiro Masaki William Lovell Chris Hamlett Susanne Saalau-Bethell Brent Graham

UNLABELLED Hepatitis C virus (HCV) NS3 is a multifunctional protein composed of a protease domain and a helicase domain linked by a flexible linker. Protease activity is required to generate viral nonstructural (NS) proteins involved in RNA replication. Helicase activity is required for RNA replication, and genetic evidence implicates the helicase domain in virus assembly. Binding of protease i...

Journal: :Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2014
Andreas Kyvernitakis Elias Jabbour Harrys A Torres

TO THE EDITOR—Patients with hepatitis C virus (HCV) genotype 1 infection should receive 12 weeks of triple combination therapy with the first-generation HCV protease inhibitor telaprevir, pegylated interferon (peg-IFN) alfa-2a or alfa-2b, and ribavirin (RBV), followed by 12 or 36 weeks of double therapy with pegIFN and RBV [1]. We report a case of sustained virologic response (SVR) achieved aft...

Journal: :Nature Reviews Gastroenterology & Hepatology 2012

2014
Y Karino I Ozeki S Hige M Kimura T Arakawa T Nakajima Y Kuwata T Sato T Ohmura J Toyota

We aimed to examine the relationship between renal dysfunction and anaemia that may develop during combination therapy involving pegylated interferon, ribavirin and telaprevir (PEG-IFN/RBV/TVR) for the treatment of chronic hepatitis C. Sixty-eight patients with genotype 1b high viral loads were treated with PEG-IFN/RBV/TVR. Peg-IFN and RBV doses were administered according to body weight. TVR w...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید